Kura Oncology (KURA) to Release Earnings on Thursday

Key Points

• Kura Oncology (NASDAQ: KURA) is set to release its Q2 2025 earnings on Thursday, August 7th, with analysts expecting earnings of $0.15 per share and revenue of $64.95 million.
• The company's previous quarterly earnings report showed a loss of ($0.66) per share, missing estimates, and revenues of $14.11 million, significantly under expectations.
• Kura Oncology's stock is currently trading at $6.02 after a 0.5% decline, with a market capitalization of $521.15 million and a consensus rating of "Moderate Buy."

Kura Oncology (NASDAQ:KURA - Get Free Report) is expected to be releasing its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Kura Oncology to post earnings of $0.15 per share and revenue of $64.95 million for the quarter.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The firm had revenue of $14.11 million for the quarter, compared to analysts' expectations of $39.08 million. On average, analysts expect Kura Oncology to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Kura Oncology Stock Down 0.5%

Kura Oncology stock traded down $0.03 during midday trading on Friday, hitting $6.02. 1,187,968 shares of the stock were exchanged, compared to its average volume of 1,392,191. Kura Oncology has a 52-week low of $5.41 and a 52-week high of $21.57. The stock has a market capitalization of $521.15 million, a price-to-earnings ratio of -2.87 and a beta of 0.40. The business's 50-day moving average price is $6.16 and its 200-day moving average price is $6.75. The company has a quick ratio of 8.07, a current ratio of 8.07 and a debt-to-equity ratio of 0.02.

Institutional Trading of Kura Oncology

A hedge fund recently bought a new stake in Kura Oncology stock. Strs Ohio purchased a new stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 21,700 shares of the company's stock, valued at approximately $143,000.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on KURA shares. Mizuho cut their price target on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, May 19th. HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Kura Oncology in a report on Monday, April 28th. Wall Street Zen cut shares of Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Wedbush reaffirmed an "outperform" rating and issued a $36.00 price objective on shares of Kura Oncology in a research report on Friday, June 20th. Finally, Barclays lowered their price objective on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Kura Oncology presently has a consensus rating of "Moderate Buy" and an average target price of $24.50.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.